Skip to main
STTK

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs is viewed favorably because its selective DR3-targeting platform could address a clear class-wide weakness in anti-TL1A programs—immunogenicity—while preserving strong efficacy potential in inflammatory bowel disease and hidradenitis suppurativa. The lead asset SL-325 showed a 3.7% ADA rate in Phase 1, durable DR3 blockade, full occupancy at low dose, and dose-proportional PK supporting quarterly dosing, while the Phase 2b Crohn’s study was expanded to ~232 patients with topline data expected in 1H28. Financially, existing cash is expected to fund operations into 2029, and risk-adjusted modeling assigns meaningful value to SL-325 across Crohn’s, UC, and HS, with added upside from SL-846.

Bears say

Shattuck Labs is a high-risk biotechnology story whose value depends heavily on SL-325 and a small pipeline of early-stage DR3 assets, leaving it exposed to clinical failure, safety signals, immunogenicity, and regulatory delays that could derail development or slow uptake. Competition around inflammatory targets is intensifying, and the company also faces legal uncertainty around patent protection plus manufacturing and commercial execution risks that could weaken its position even if data remain encouraging. Financially, it does not anticipate profitability for several years and expects to require additional funding to advance trials, with only a 20% PoS for IBD and a valuation model that is highly sensitive to assumptions and timeline shifts.

Shattuck Labs (STTK) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 8 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of Oct 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.